|
Double-blind, randomized phase 3 study to compare efficacy and safety of the biosimilar CT-P10 to rituximab combined with CVP therapy in patients with previously untreated advanced-stage follicular lymphoma. |
|
|
Honoraria - Johnson & Johnson; Roche |
Consulting or Advisory Role - Celltrion; Johnson & Johnson |
Research Funding - Celgene; Celltrion; Dong-A Socio; Johnson & Johnson; Kirin Pharmaceuticals; Novartis; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
Jose Angel Hernandez Rivas |
Other Relationship - Celltrion |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bayer; Janssen; Pfizer; Roche |
Consulting or Advisory Role - Bayer; Janssen; Pfizer; Roche |
Research Funding - Janssen; Roche |
|
|
Speakers' Bureau - Celltrion |
Travel, Accommodations, Expenses - Celltrion |
|
|
Honoraria - Celltrion; Janssen; Takeda |
Consulting or Advisory Role - Celltrion; Meiji Seika Kaisha; Mundipharma |
Research Funding - Celltrion (Inst); SymBio Pharmaceuticals (Inst) |
|
|
|
|
Stock and Other Ownership Interests - Celltrion |
Travel, Accommodations, Expenses - Celltrion |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Celltrion |
Travel, Accommodations, Expenses - Celltrion |
|
|
Consulting or Advisory Role - Celgene; Celltrion; ERYTECH Pharma; MorphoSys; Mundipharma; Novartis; Pfizer; Roche; Takeda |
Research Funding - Celgene (Inst) |
Expert Testimony - Gilead Sciences |